A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever

• Published in: npj vaccines Vol. 9; no. 1; p. 86
• Main Authors: Hawman, David W., Leventhal, Shanna S., Meade-White, Kimberly, Khandhar, Amit, Murray, Justin, Lovaglio, Jamie, Shaia, Carl, Saturday, Greg, Hinkley, Troy, Erasmus, Jesse, Feldmann, Heinz
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20.05.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/326/590/2293; 631/326/596; Biomedical and Life Sciences; Biomedicine; Fever; Geographical distribution; Immunization; Immunogenicity; Infectious Diseases; Medical Microbiology; Public Health; Vaccine; Vaccines; Virology
• ISSN: 2059-0105; 2059-0105
• DOI: 10.1038/s41541-024-00887-z

Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne febrile illness with a wide geographic distribution. In recent years the geographic range of Crimean-Congo hemorrhagic fever virus (CCHFV) and its tick vector have increased, placing an increasing number of people at risk of CCHFV infection. Currently, there are no widely available vaccines, and although the World Health Organization recommends ribavirin for treatment, its efficacy is unclear. Here we evaluate a promising replicating RNA vaccine in a rhesus macaque ( Macaca mulatta) model of CCHF. This model provides an alternative to the established cynomolgus macaque model and recapitulates mild-to-moderate human disease. Rhesus macaques infected with CCHFV consistently exhibit viremia, detectable viral RNA in a multitude of tissues, and moderate pathology in the liver and spleen. We used this model to evaluate the immunogenicity and protective efficacy of a replicating RNA vaccine. Rhesus macaques vaccinated with RNAs expressing the CCHFV nucleoprotein and glycoprotein precursor developed robust non-neutralizing humoral immunity against the CCHFV nucleoprotein and had significant protection against the CCHFV challenge. Together, our data report a model of CCHF using rhesus macaques and demonstrate that our replicating RNA vaccine is immunogenic and protective in non-human primates after a prime-boost immunization.